Medicure, Inc. 是一家从事心血管治疗药物的研究、临床开发和商业化的制药公司。公司总部位于加拿大曼尼托巴省温尼伯市,目前拥有25名全职员工。公司专注于为美国市场的患者和处方医生开发和商业化药品及医疗保健产品。其主要业务是营销和分销 AGGRASTAT(盐酸替罗非班)注射剂和 ZYPITAMAG(匹伐他汀)片剂,这些产品通过公司在美子公司 Medicure Pharma Inc. 销售。公司还运营 Marley Drug Inc.(Marley Drug),这是一家药房子公司,服务范围覆盖美国50个州、华盛顿特区和波多黎各。Marley Drug 致力于通过卓越的客户服务和免费送货上门服务,改善所有美国人获得药物的机会。AGGRASTAT 适用于降低非ST段抬高急性冠脉综合征患者发生血栓性心血管事件的风险。此外,公司还在开发磷酸吡哆醛5'-磷酸类似物(P5P类似物)、其制备工艺以及含有P5P类似物的制剂。
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for MCUJF. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: MCUJF is a Sell candidate.
MCUJF stock price ended at $0.79 on 星期四, after dropping 13.19%
On the latest trading day Feb 12, 2026, the stock price of MCUJF fell by 13.19%, dropping from $0.79 to $0.79. During the session, the stock saw a volatility of 0.00%, with prices oscillating between a daily low of $0.79 and a high of $0.79. On the latest trading day, the trading volume for MCUJF decreased by 5.1K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 1.5K shares were traded, with a market value of approximately --.